Hasgul Zeynep, Spanjaart Anne, Javed Sumreen, Akhavan Ali, Kersten Marie José, Jalali Mohammad S
MGH Institute for Technology Assessment, Harvard Medical School, 125 Nashua St, Boston, MA, 02114, USA.
Department of Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.
Qual Life Res. 2025 Jan;34(1):273-286. doi: 10.1007/s11136-024-03810-0. Epub 2024 Oct 30.
Understanding health-related quality of life (HRQoL) dynamics is essential for assessing and improving treatment experiences; however, clinical and observational studies struggle to capture their full complexity. We use simulation modeling and the case of Chimeric Antigen Receptor T-cell therapy-a type of cancer immunotherapy that can prolong survival, but carries life-threatening risks-to study HRQoL dynamics.
We developed an exploratory system dynamics model with mathematical equations and parameter values informed by literature and expert insights. We refined its feedback structure and evaluated its dynamic behavior through iterative interviews. Model simulated HRQoL from treatment approval through six months post-infusion. Two strategies-reducing the delay to infusion and enhancing social support-were incorporated into the model. To dynamically evaluate the effect of these strategies, we developed four metrics: post-treatment HRQoL decline, recovery time to pre-treatment HRQoL, post-treatment HRQoL peak, and durability of the peak.
Model captures key interactions within HRQoL, providing a nuanced analysis of its continuous temporal dynamics, particularly physical well-being, psychological well-being, tumor burden, receipt and efficacy of treatment, side effects, and their management. Model analysis shows reducing infusion delays enhanced HRQoL across all four metrics. While enhanced social support improved the first three metrics for patients who received treatment, it did not change durability of the peak.
Simulation modeling can help explore the effects of strategies on HRQoL while also demonstrating the dynamic interactions between its key components, offering a powerful tool to investigate aspects of HRQoL that are difficult to assess in real-world settings.
了解健康相关生活质量(HRQoL)动态对于评估和改善治疗体验至关重要;然而,临床研究和观察性研究难以全面把握其复杂性。我们利用模拟建模,并以嵌合抗原受体T细胞疗法为例——这是一种癌症免疫疗法,可延长生存期,但存在危及生命的风险——来研究HRQoL动态。
我们开发了一个探索性系统动力学模型,其数学方程和参数值参考了文献及专家见解。我们优化了其反馈结构,并通过反复访谈评估其动态行为。该模型模拟了从治疗获批到输液后六个月的HRQoL。模型纳入了两种策略——减少输液延迟和加强社会支持。为动态评估这些策略的效果,我们制定了四个指标:治疗后HRQoL下降、恢复到治疗前HRQoL的时间、治疗后HRQoL峰值以及峰值的持续时间。
该模型捕捉到了HRQoL中的关键相互作用,对其连续的时间动态进行了细致入微的分析,特别是身体健康、心理健康、肿瘤负担、治疗的接受情况和疗效、副作用及其管理。模型分析表明,减少输液延迟在所有四个指标上均提高了HRQoL。虽然加强社会支持改善了接受治疗患者的前三个指标,但并未改变峰值的持续时间。
模拟建模有助于探索策略对HRQoL的影响,同时展示其关键组成部分之间的动态相互作用,为研究在现实环境中难以评估的HRQoL方面提供了一个强大的工具。